Janus Kinase Inhibitor

Upadacitinib maintains its efficacy over 56 weeks in patients with psoriatic arthritis who had a prior inadequate response to at least one biologic disease-modifying antirheumatic drug, according to data presented at the EULAR 2021 Virtual Congress.

Tofacitinib 2 mg twice daily demonstrated “significantly greater” efficacy than placebo in adults with ankylosing spondylitis, according to researchers writing in the Annals of the Rheumatic Diseases.

Selective janus kinase 1 inhibitor, SHR0302, induced clinical response and remission among patients with moderate to severe ulcerative colitis, according to a study at Digestive Disease Week.

Janus kinase inhibitors “may prove useful” in a wider range of immune-mediated inflammatory diseases, including refractory cutaneous dermatomyositis, chronic plaque psoriasis and other conditions, according to a speaker here.

Patients with rheumatoid arthritis in the United States made “substantial” medication changes in the first 3 months of the COVID-19 pandemic, with and without physician guidance, according to data published in Arthritis Care & Research.

Studies examining the immunopathogenesis of COVID-19 and its link to immune system dysregulation are providing an “unparalleled opportunity” to learn more about autoimmunity, according to a review published in Pathogens and Immunity.

Upadacitinib is equivalent or superior to adalimumab in improving patient-reported outcomes among those with rheumatoid arthritis and an inadequate response to methotrexate, according to data published in Rheumatology.

A speaker at South Beach Symposium Medical Dermatology Summit discussed the JAK inhibitors that are currently on the market and their applications in treating alopecia areata.

For Pfizer and its JAK inhibitor, Xeljanz, February rang in with the sound of alarm bells, as the FDA issued its third warning about the drug in 2 years.

Undeterred by the FDA’s rejection of filgotinib over testicular toxicity concerns, the United Kingdom’s National Institute for Health and Clinical Excellence has endorsed its use among eligible patients on England’s National Health Service.